Summary of results using chemotherapy to treat PTLD in solid organ transplant patients.81
| Series . | Regimen . | No. Patients . | CR Rate . | Relapse Rate . | Rejection Rate . | Toxic Death* . | 1-Year DFS . |
|---|---|---|---|---|---|---|---|
| Swinnen, et al21 | ProMACE-CytaBOM | 11 | 55% | 0% | 0% | 27% | 45% |
| Morrison, et al12 | CHOP +/- Bleo, COMLA, M-BACOD, VACOP-B, Ifos/VP-16/Dex | 9 | 11% | 0% | 0% | NR | 11% |
| Garrett, et al22 | CHOP | 4 | 100% | 0% | 0% | 25% | 75% |
| Hayashi, et al23 | CY, Adria, VCR, MTX, AraC + IT, ABVD-MOPP** (2 HD) | 10 | 80% | 10% | 0% | 0% | 70% |
| Gross, et al | CY/Pred*** | 35 | 83% | 14% | 11% | 6% | 81% |
| Abbreviations: Promace-CytoBOM, prednisone, vincristine (VCR), doxorubicin (Adria), methotrexate (MTx), cytosine arabinoside (Ara-C), bleomycin (Bleo), cyclophosphamide (Cy), etoposide (Vp 16); CHOP, Cy, Adria, VCR, prednisone; COMLA, Cy, VCR, MTx, Leukcovorin, Ara-C; M-BACOD, Mtx, Bleo, Cy, VCR, dexamethasone (Dex); VACOP-B, Vp6, Adria, Cy, VCR, Bleo; Ifos, ifosfamide; IT, intrathecal; CR, complete remission; DFS, disease-free survival | |||||||
| Series . | Regimen . | No. Patients . | CR Rate . | Relapse Rate . | Rejection Rate . | Toxic Death* . | 1-Year DFS . |
|---|---|---|---|---|---|---|---|
| Swinnen, et al21 | ProMACE-CytaBOM | 11 | 55% | 0% | 0% | 27% | 45% |
| Morrison, et al12 | CHOP +/- Bleo, COMLA, M-BACOD, VACOP-B, Ifos/VP-16/Dex | 9 | 11% | 0% | 0% | NR | 11% |
| Garrett, et al22 | CHOP | 4 | 100% | 0% | 0% | 25% | 75% |
| Hayashi, et al23 | CY, Adria, VCR, MTX, AraC + IT, ABVD-MOPP** (2 HD) | 10 | 80% | 10% | 0% | 0% | 70% |
| Gross, et al | CY/Pred*** | 35 | 83% | 14% | 11% | 6% | 81% |
| Abbreviations: Promace-CytoBOM, prednisone, vincristine (VCR), doxorubicin (Adria), methotrexate (MTx), cytosine arabinoside (Ara-C), bleomycin (Bleo), cyclophosphamide (Cy), etoposide (Vp 16); CHOP, Cy, Adria, VCR, prednisone; COMLA, Cy, VCR, MTx, Leukcovorin, Ara-C; M-BACOD, Mtx, Bleo, Cy, VCR, dexamethasone (Dex); VACOP-B, Vp6, Adria, Cy, VCR, Bleo; Ifos, ifosfamide; IT, intrathecal; CR, complete remission; DFS, disease-free survival | |||||||